Clinical Trial Update: Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating light-activated talaporfin disodium for lower urinary tract symptoms due to benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Talaporfin disodium (talaporfin disodium)

Snippet

Sponsor: Light Sciences Oncology | Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 2 | Status: COMPLETED